Cite
HARVARD Citation
Demarchi, M. et al. (2021). TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects. Pharmacology research & perspectives. 9 (4), p. n/a. [Online].